Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)
National Institutes of Health Nationwide (Federal)
Tell us about your organization and we'll show you whether this grant fits, and why.
Free to start. No credit card required.
Deadline
November 17, 2026
Region
Nationwide (Federal)
Funder type
Federal Government
For
Nonprofits & businesses
Sectors
Health & Human Services
About this program
Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed) — U.S. federal funding opportunity (PAR-25-096) from National Institutes of Health. See grants.gov for full eligibility and details.
Official program page Last verified October 5, 2026 by the Happy Grants engine
Is this grant worth your time?
Create a free account and Happy Grants scores this program, and 2,300+ others, against your organization’s profile in about a minute, with the reasons explained.
See your match score, freeSimilar grants
- Lasker Clinical Research Scholar's Program (Si2/R00 Clinical Trial Optional)National Institutes of Health Jul 7, 2028
- Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed)National Institutes of Health Jan 7, 2028
- Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Not Allowed)National Institutes of Health Jan 7, 2028
- Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional)National Institutes of Health Nov 18, 2026
- Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional)National Institutes of Health Jan 28, 2028
- Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant (Parent T32)National Institutes of Health May 4, 2028